Interventional cardiology at Yale-New Haven is led by an expert team of physicians experienced in diagnosing and treating the full range of coronary artery and peripheral vascular diseases.
Our interventional cardiologists perform than 10,000 procedures a year on patients of all ages from around the world in advanced cardiac catheterization laboratories. They lead the way in the search for better nonsurgical methods for diagnosing and treating patients with narrowed blood vessels. These methods include innovative intracoronary stent platforms, novel techniques and devices to treat completely blocked arteries, management of advanced blockages in multiple heart vessels and nonsurgical methods to treat valvular heart disease. The goals for the interventional team include improving patient outcomes, minimizing the need for open-heart surgery and helping patients who have poor survival and medical therapy options.
Yale-New Haven interventional cardiologists are engaged in leading-edge innovations, including the development and first intracoronary stent placement in New England, early development and utilization of atherectomy devices, novel gene and cell-based therapies to attempt to “grow” new heart tissue and blood vessels, and technique and technology development for the successful treatment of chronically blocked arteries.
Yale-New Haven Hospital is among a select number of hospitals in the country, and the first hospital in Connecticut, to offer transcatheter aortic valve replacement (TAVR) as a treatment option for patients with severe aortic stenosis. The transcatheter procedure is easier on patients, typically offers a shorter recovery time than traditional surgery, and provides doctors with a new option to treat patients who are at increased risk for open-heart surgery.
Some of the many procedures offered at YNHH include:
- Percutaneous coronary interventions
- Percutaneous peripheral interventions
- Carotid artery interventions
- Direct interventions for acute myocardial infarction (heart attack)
- Minimally invasive valve repair
- Structural heart disease repair
Saving times, saving lives
At Yale-New Haven Hospital, rapid time-to-treatment is a priority. Yale-New Haven's median D2B time is 68 minutes, significantly shorter than the American Heart Association's recommended standard of 90 minutes.
With a heart attack, time is everything. In fact your chances of survival are dramatically increased if the blockage can be treated within 90 minutes of your arrival at the hospital. Known as the door-to-balloon time (D2B), it is a performance of the time between patient entrance in the emergency department and when angioplasty is performed.
At Yale-New Haven, patients admitted with chest pain have a diagnostic EKG on average within six minutes of arrival and flow restored to the heart with angioplasty and stenting of the heart artery blockage within 68 minutes, when necessary. And our advancements with EMT professionals are helping to make these times even shorter.
Our busy program and interventionalists have long been engaged in leading edge innovations, including the development and first intracoronary stent placement in New England, early development and utilization of atherectomy devices, novel gene and cell based therapies to attempt to "grow" new heart tissue and blood vessels, and technique and technology development for the successful treatment of chronically blocked arteries.